Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions for the global challenges of antibiotic resistance and sepsis. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The United States Food and Drug Administration (FDA) cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately seven hours direct from positive blood cultures. The Accelerate PhenoTest BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. Its other products include Accelerate Arc system and BC Kit (Accelerate Arc Products) and Accelerate Wave system.
BörsenkürzelAXDX
Name des UnternehmensAccelerate Diagnostics Inc
IPO-datumOct 27, 1993
CEOMr. John (Jack) Phillips
Anzahl der mitarbeiter107
WertpapierartOrdinary Share
GeschäftsjahresendeOct 27
Addresse3950 S Country Club Rd Ste 470 Bldg 3-307
StadtDENVER
BörseBolsa Mexicana de Valores S.A. de C.V.
LandUnited States of America
Postleitzahl80203
Telefon13038638088
Websitehttps://acceleratediagnostics.com/
BörsenkürzelAXDX
IPO-datumOct 27, 1993
CEOMr. John (Jack) Phillips
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten